medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2017, Número 4

<< Anterior Siguiente >>

Ann Hepatol 2017; 16 (4)


A Case Report of Hepatocellular Carcinoma 5 Years After HBsAg Loss in Chronic Hepatitis Delta: How Long Surveillance is Required?

Escolà-Vergé L, Riveiro-Barciela M, Buti M

Idioma: Ingles.
Referencias bibliográficas: 11
Paginas: 630-632
Archivo PDF: 107.91 Kb.


RESUMEN

Sin resumen.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Farci P, Niro GA. Clinical features of hepatitis D. Semin Liver Dis 2012; 32: 228-36.

  2. Rizzetto M, Smedile A. Pegylated interferon therapy of chronic hepatitis D: in need of revision. Hepatology 2015; 61: 1109-11.

  3. Rasshofer R, Buti M, Esteban R, Roggendorf M. Demonstration of hepatitis D virus RNA in patients with chronic hepatitis. J Infect Dis 1988; 157: 191-5.

  4. Romeo R, Del Ninno E, Rumi M, Russo A, Sangiovanni A, de Franchis R, Ronchi G, et al. A 28-year study of the course of hepatitis Delta infection: a risk factor for cirrhosis and hepatocellular carcinoma. Gastroenterology 2009; 136: 1629-38.

  5. Yuen MF, Wong DK, Fung J, Ip P, But D, Hung I, Lau K, et al. HBsAg Seroclearance in chronic hepatitis B in Asian patients: replicative level and risk of hepatocellular carcinoma. Gastroenterology 2008; 135: 1192-9.

  6. Buti M, Homs M, Rodriguez-Frias F, Funalleras G, Jardi R, Sauleda S, Tabernero D, et al. Clinical outcome of acute and chronic hepatitis delta over time: a long-term follow-up study. J Viral Hepat 2011; 18: 434-42.

  7. Niro GA, Smedile A, Ippolito AM, Ciancio A, Fontana R, Olivero A, Valvano MR, et al. Outcome of chronic delta hepatitis in Italy: a long-term cohort study. J Hepatol 2010; 53: 834-40.

  8. Wranke A, Calle Serrano B, Heidrich B, Kirschner J, Bremer B, Lehmann P, Hardtke S, et al. Antiviral treatment and liverrelated complications in hepatitis delta. Hepatology 2016. doi: 10.1002/hep.28876.

  9. Marcellin P, Gane E, Buti M, Afdhal N, Sievert W, Jacobson IM, Washington MK, et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet 2013; 381: 468-75.

  10. Kim WR, Loomba R, Berg T, Aguilar Schall RE, Yee LJ, Dinh PV, Flaherty JF, et al. Impact of long-term tenofovir disoproxil fumarate on incidence of hepatocellular carcinoma in patients with chronic hepatitis B. Cancer 2015; 121: 3631-8.

  11. Hosaka T, Suzuki F, Kobayashi M, Seko Y, Kawamura Y, Sezaki H, Akuta N, et al. Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection. Hepatology 2013; 58: 98-1078.




2020     |     www.medigraphic.com